EXEL Exelixis, Inc.

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer. The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data. The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about. To put this regulatory update in context,...

Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer

Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]

Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki

Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies. Speaking at a company event, Andrew Peters, Exelixis’ senior vice p

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread.

Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment.

Exelixis Inc (NASDAQ:EXEL) shares fell 3. 5% in premarket trading Friday after the company said the US Food and Drug Administration extended the review period for its new drug application for zanzalintinib by three months.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.8% and the actively trad

Meanwhile, several stocks showed bullish signs, including software giant ServiceNow. Digital bank Dave Inc., commodities trading platform Marex Group, senior living REIT Welltower and cancer treatment developer Exelixis round out the list of stocks to watch in or near buy zones. ServiceNow is in a buy zone after breaking out of a cup base with a buy point of 139.20 on Aug. 28, reclaiming the entry on Sept. 2.

Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone.

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis shares hit an all-time high Wednesday. Exelixis holds third place in IBD's profitable biotech group, according to IBD Stock Checkup. The company has cancer medications approved by the U.S. Food and Drug Administration as well as treatments in its pipeline.

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a

Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.

A buyback funded by one oncology drug is concentrating each holder's claim while the next franchise waits on a regulatory decision.

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.

In early August 2026, Exelixis reported second-quarter results showing revenue of US$628.69 million and net income of US$212.05 million, with earnings per share increasing versus the prior year, but slightly trailing revenue expectations. Alongside lowering its 2026 revenue outlook to US$2.50 billion–US$2.55 billion, the company highlighted slower growth in the neuroendocrine tumor indication and continued investment in its zanzalintinib pipeline and share repurchase activities. We’ll now...

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Exelixis Inc (EXEL) reports robust Q2 2026 results with $629M in revenues, while navigating slower NET adoption and advancing its zanzalintinib pipeline toward key regulatory milestones.

Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program f

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Exelixis stock toppled late Wednesday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations.

Expand Energy (NASDAQ:EXE) said its second-quarter operating performance and capital allocation actions reinforced its strategy of becoming an integrated natural gas company, highlighting debt reduction, share repurchases, organic lease additions and its planned acquisition of natural gas marketer T

They are riding strong tailwinds that could lift them higher.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.